How to choose a research peptide in Mexico

Which is the “best” research peptide?

The question has no answer in the abstract, and any list that gives one without context is selling something. A compound is suitable or not depending on the experimental model, the route studied and the quality of the literature behind it. What can be compared objectively is something else: which chemical identity it has defined, how much primary evidence exists, whether that evidence is preclinical or clinical, and what analytical documentation comes with the material.

This framework sorts the catalogue by those criteria, not by popularity.

Criterion 1: how solid is the evidence?

It is the biggest difference between compounds that are often grouped together as if they were equivalent.

• With active regulatory approval. Only tesamorelin fits here: approved by the FDA in 2010 for a specific indication, with a complete clinical programme. Its own prescribing information states that it is not indicated for weight control.
• Molecule approved as a medicine, different RUO material. Semaglutide and tirzepatide are registered in Mexico as prescription drugs. The research reagent shares the molecule but is not that medicine.
• Broad, replicated preclinical base. MOTS-c has work from independent groups since it was first described in 2015.
• Broad but concentrated preclinical base. BPC-157 has more than 200 publications, but over 80% come from a single group, and a debate about that concentration was published in 2025.
• Scarce literature or hard to assess independently. Several compounds in the catalogue fall here, and we say so on their product page instead of glossing over it.

Criterion 2: does it have a verifiable chemical identity?

A single compound has a CAS number, molecular formula, molecular weight and, if it is a peptide, a sequence. Those four data points make it possible to check the material received against the Certificate of Analysis and against open sources.

Blends do not have them. GLOW, KLOW or the CJC-1295 and ipamorelin combination contain several different molecules, so they do not have a CAS number or formula of their own. The practical consequence is a quality criterion you can demand from any supplier: the COA of a blend must report the identity and purity of each component separately. A certificate with a single aggregate purity value does not make it possible to verify what is inside the vial.

Criterion 3: which presentation makes sense?

The higher the strength, the lower the price per milligram. But the cheapest vial per mg is only the best buy if it is used within the shelf life of the reconstituted solution. The price per milligram table does that division for the whole catalogue.

When you should NOT buy from us

For transparency, and because a recommendation that never says no is a useless recommendation:

• NeoPeptidos is NOT the right option for anyone seeking medical treatment. The products are research reagents, not medicines, and they do not replace a clinical consultation or a prescription.
• For molecules that exist as approved medicines registered in Mexico (semaglutide and tirzepatide among them), the right route for therapeutic use is a doctor and a pharmacy, not a reagent supplier. They share the molecule, but not the manufacturing standards, stability controls, packaging, labelling or health responsibility.
• We do not publish human administration protocols or recommended doses for people. The dosing information on this site corresponds to ranges reported in the scientific literature, for documentary purposes.
• The evidence available for most of these compounds is preclinical: cell culture studies and animal models. Very few have controlled clinical trials in humans, and we state this compound by compound instead of generalising.
• We do not ship outside Mexico.

Frequently asked questions